top of page
  • Active, not recruiting

NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With RRMM Myeloma

NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

Carfilzomib Multiple Myeloma Expanded Access Protocol

NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease



The purpose of this study is to expand upon the safety data for carfilzomib by providing expanded access to patients with relapsed and refractory multiple myeloma who are unable to enroll in any other ongoing carfilzomib trial.


Sponsor

Amgen


Collaborator

Multiple Myeloma Research Foundation


 

ClinicalTrials.gov Identifier: NCT01410500

Official Title: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

First Posted : August 5, 2011

Click here to see details on ClinicalTrials.gov

 
 

Drug: Carfilzomib

 

Location

United States



Comments


Posts Archive
bottom of page